A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of the mTOR Inhibitor (RAD001) in Combination with the IGF-1R Antagonist (R1507) in Patients with Advanced Solid Tumors.

Trial Profile

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Effect on Tumor Response of the mTOR Inhibitor (RAD001) in Combination with the IGF-1R Antagonist (R1507) in Patients with Advanced Solid Tumors.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Dec 2013

At a glance

  • Drugs Everolimus (Primary) ; Teprotumumab
  • Indications Pancreatic cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Dec 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Sep 2012 Planned end date changed from 1 Sep 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top